Additionally, the availability of specific inhibitors against some of the reported mutations (e.g., FLT3, NPM1) will add additional treatment options for patients with CML-BP. This evidence concerns the gene NPM1 and chronic myelogenous leukemia, BCR-ABL1 positive.